IL15 and neoplasm: The efficacy of CAR T cells has been limited in patients with solid tumors13 in part due to the tumor microenvironment (TME), which contains inhibitory signals that block immune responses and lacks supportive factors including cytokines (i.e. interleukin-15 (IL15)) required for survival and optimal function of tumor-specific T cells1.